NASDAQ:NITE

Nightstar Therapeutics (NITE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$25.41
$25.41
50-Day Range
$25.41
$25.41
52-Week Range
$9.59
$29.55
Volume
40 shs
Average Volume
185,808 shs
Market Capitalization
$852.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NITE stock logo

About Nightstar Therapeutics Stock (NASDAQ:NITE)

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.

NITE Stock News Headlines

Thank you for supporting The Big Night In
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Day and night
Last Night tickets information
Nightstar Therapeutics plc Sponsored ADR News
NITE_old Historical Data
Sensorion appoints Aniz Girach as Independent Board Member
See More Headlines
Receive NITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nightstar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2018
Today
4/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:NITE
Fax
N/A
Employees
47
Year Founded
N/A

Profitability

Net Income
$-36,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.89 per share

Miscellaneous

Free Float
N/A
Market Cap
$852.25 million
Optionable
Not Optionable
Beta
2.84
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. David Fellows (Age 62)
    CEO & Director
  • Mr. Senthil Vel Sundaram (Age 41)
    Chief Financial Officer
  • Dr. Gregory Scott Robinson (Age 60)
    Chief Scientific Officer
  • Brian Luque
    Sr. Mang. of Investor Relations
  • Mr. Seokho Bryan Yoon Esq. (Age 40)
    Gen. Counsel & Sec.

NITE Stock Analysis - Frequently Asked Questions

How were Nightstar Therapeutics' earnings last quarter?

Nightstar Therapeutics PLC (NASDAQ:NITE) announced its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.13.

What other stocks do shareholders of Nightstar Therapeutics own?
When did Nightstar Therapeutics IPO?

Nightstar Therapeutics (NITE) raised $76 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.

This page (NASDAQ:NITE) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners